MIBG for Refractory Neuroblastoma and Pheochromocytoma

  • End date
    Dec 23, 2022
  • participants needed
  • sponsor
    Masonic Cancer Center, University of Minnesota
Updated on 23 March 2022
total body irradiation
ejection fraction
monoclonal antibodies
stem cell infusion
bone marrow procedure
refractory neuroblastoma
antibody therapy
myelosuppressive chemotherapy


This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.


Primary Objective is to provide access to therapy with 131I-MIBG for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma.

Secondary Objective is to assess disease response to 131I-MIBG therapy for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma.

Tertiary Objectives are to 1) gain more information about the toxicities of 131I-MIBG therapy; 2) assess improvement of symptoms, including pain and fatigue, for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are receiving 131I-MIBG therapy.

  • The therapeutic dose of 131I-MIBG will be based on the following:
    1. Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.
    2. Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.
    3. Dose of > 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available.
  • A urinary catheter and intravenous fluids will be used for bladder protection, and potassium iodide solution for thyroid Protection.
  • G-CSF is recommended for patients with ANC less than 750 after MIBG infusion.
  • hematopoietic stem cell infusion is recommended for patients with grade 4 hematologic toxicity following 131I-MIBG therapy that continues to have an ANC <200 on G-CSF without signs of recovery for >2 weeks and any patient requiring platelet transfusion more than two times weekly for 4 consecutive weeks.
  • Follow-up will be done until disease progression, death or other therapies are initiated.

Condition Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Treatment G-CSF, 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, hematopoietic stem cell infusion
Clinical Study IdentifierNCT01850888
SponsorMasonic Cancer Center, University of Minnesota
Last Modified on23 March 2022


Yes No Not Sure

Inclusion Criteria

Relapsed/refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine catecholamines with typical neuroblastoma cells in the bone marrow
Metastatic pheochromocytoma
Age >1 year and able to cooperate with radiation safety restrictions during therapy
Karnofsky or Lansky performance status of ≥ 50%
Life expectancy: ≥ at least 8 weeks
Disease status: Failure to respond to standard therapy or development of progressive disease at any time
Disease must be evaluable by MIBG scan. A positive MIBG scan must be present within 8 weeks prior to study entry and subsequent to any intervening therapy. If the patient has only one MIBG positive lesion and that lesion was radiated, a biopsy must be done at least 4 weeks after radiation was completed and must show viable neuroblastoma
Stem Cells: Patients must have a hematopoietic stem cell product available for reinfusion after MIBG treatment at doses of > 12 mCi/kg
Have acceptable organ function as defined below within 7 days of enrollment
Bone Marrow: ANC ≥750 X 109 /L and platelets ≥50,000 X 109 /L without transfusion if stem cells are not available (any ANC or platelet allowed if stem cells available)
Renal: Creatinine ≤3x upper limit of normal
Hepatic: Bilirubin ≤2x upper limit of normal; AST/ALT ≤10x upper limit of normal
Cardiac: Ejection fraction ≥45% on echocardiogram
Pulmonary: normal lung function as manifested by no dyspnea and/or oxygen saturation ≥ 88% on room air
Myelosuppressive chemotherapy: At least 2 weeks should have elapsed since any chemotherapy causing myelosuppression
Prior Therapy: Patients must have recovered from all acute toxicities (defined as
CTCAE 4.0 ≤ grade 1) associated with any prior therapy, and
Biologic (anti-neoplastic agent): At least 7 days should have elapsed since the completion of therapy with a biologic agent
Monoclonal antibodies: At least 3 half-lives should have elapsed since therapy with a monoclonal antibody
Radiation therapy: Three-months should have elapsed in the case of completing radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation). For all other sites of radiation, at least 2 weeks should have relapsed
Cytokine therapy (e.g. G-CSF, GM-CSF, IL-6, IL-2): must be discontinued a minimum of 24 hours prior to MIBG therapy
Voluntary written informed consent

Exclusion Criteria

Patients with disease of any major organ system that would compromise their ability to withstand therapy
Because of the teratogenic potential of the study medication, no patients who are pregnant or lactating will be allowed. Patients of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus
Known allergy to any of the agents or their ingredients used in this study
Patients who are on hemodialysis
Patients with untreated positive blood cultures or progressive infections as assessed by radiographic studies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note